EpimAb Biotherapeutics Updates IPO Filing: China’s TCE Pioneer Turns Profitable Through Landmark Licensing Deals
EpimAb Biotherapeutics, a Chinese T-cell engager (TCE) pioneer, updated its HK IPO filing. It has achieved profitability through licensing deals worth over $2.1 billion.
12/19/20251 min read